Tirzepatide is a once-weekly injectable medication that a Company is developing to treat type 2 diabetes. It is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has shown promising results in clinical trials.
Tirzepatide works by stimulating the release of insulin and suppressing the release of glucagon, which helps to lower blood sugar levels. It also slows down the rate at which food is absorbed into the bloodstream, which can help to reduce post-meal spikes in blood sugar.
In clinical trials, tirzepatide is more effective at lowering blood sugar levels than other GLP-1 receptor agonists, such as dulaglutide and semaglutide. It has also been shown to promote weight loss, which is a significant benefit for people with type 2 diabetes who often struggle with obesity.
One of the most significant advantages of tirzepatide is its once-weekly dosing schedule. This significantly improves over other GLP-1 receptor agonists, which typically require daily or twice-daily injections. The convenience of a once-weekly injection could make it easier for people with type 2 diabetes to adhere to their treatment regimen.
NOT FOR HUMAN CONSUMPTION
RESEARCH CHEMICALS ONLY